Palbociclib is a prescription anticancer medicine that should only be used under the supervision of an appropriately qualified healthcare professional experienced in cancer treatment.
The medicine belongs to a class known as cyclin-dependent kinase 4 and 6 inhibitors, commonly called CDK4/6 inhibitors. Palbociclib is used in specific treatment settings for certain hormone receptor-positive, HER2-negative advanced or metastatic breast cancers according to applicable regulatory approvals and official product labeling.
This page provides general educational information. It does not replace the complete prescribing information for a specific Palbociclib product.
The prescribing information supplied with the actual medicine should always be considered the primary source for product-specific instructions.
Important prescribing considerations
Before prescribing Palbociclib, healthcare professionals consider the patient’s complete clinical situation.
Important considerations can include:
- Confirmed cancer diagnosis
- Hormone receptor status
- HER2 status
- Disease stage
- Previous cancer treatment
- Current medicines
- Blood-cell counts
- Treatment tolerance
- Pregnancy status where relevant
- Applicable regulatory approval
Palbociclib is not appropriate for every patient with breast cancer.
Appropriate tumor classification is essential before treatment selection.
Combination treatment
Palbociclib is generally used in combination with endocrine therapy for approved indications.
Depending on the clinical situation and applicable labeling, treatment may involve an approved endocrine partner such as an aromatase inhibitor or fulvestrant.
The choice of treatment combination depends on factors including:
- Previous endocrine therapy
- Disease progression
- Menopausal status
- Previous systemic treatment
- Current clinical condition
For some premenopausal or perimenopausal patients, ovarian suppression or ablation may be relevant to the treatment strategy.
Dosage considerations
The appropriate Palbociclib regimen must follow official prescribing information for the specific product and the instructions of the treating oncology team.
Palbociclib is available in different strengths to allow clinically directed treatment and dose modification.
The 125 mg strength is commonly referenced in Palbociclib treatment. However, some patients may require lower strengths because of adverse reactions or other clinical considerations.
Patients should never independently change:
- Their dose
- Their treatment cycle
- The number of units taken
- The timing of treatment interruption
- The timing of treatment restart
Hematologic monitoring
Palbociclib can affect blood-cell counts.
Neutropenia is one of the most important adverse reactions associated with treatment.
Healthcare professionals may monitor complete blood counts before treatment and during therapy according to applicable prescribing guidance.
Monitoring may include evaluation of:
- Neutrophils
- Total white blood cells
- Hemoglobin
- Platelets
If clinically significant abnormalities occur, treatment may require interruption, delay or dose modification.
Infection precautions
Patients receiving Palbociclib should understand the importance of reporting possible signs of infection.
Symptoms can include:
- Fever
- Chills
- Sore throat
- Persistent cough
- Other signs of infection
A patient with significant neutropenia may be more vulnerable to infection.
The oncology team should provide specific instructions about when urgent medical evaluation is required.
Respiratory safety
Official safety information for Palbociclib includes concerns regarding interstitial lung disease and pneumonitis.
Patients who develop new or worsening respiratory symptoms should receive appropriate medical evaluation.
Potential symptoms can include:
- Shortness of breath
- Difficulty breathing
- Persistent cough
Respiratory symptoms can have multiple causes, including infection, cancer progression and other medical conditions.
A healthcare professional must determine the cause.
Drug interactions
Palbociclib can interact with other medicines.
Medicines affecting CYP3A activity may significantly influence Palbociclib exposure.
Strong CYP3A inhibitors can increase exposure, while strong CYP3A inducers can decrease exposure.
A complete medication review should include:
- Prescription medicines
- Non-prescription medicines
- Herbal products
- Vitamins
- Dietary supplements
Patients should not start or stop another medicine without discussing it with their healthcare team.
Pregnancy considerations
Palbociclib may cause harm to a developing fetus.
Patients who are pregnant, may become pregnant or are planning pregnancy should discuss these issues with their healthcare professionals.
Appropriate contraception and reproductive counseling may be required according to official product information.
Product-specific information
The generic name Palbociclib can apply to products manufactured by different companies in different markets.
Therefore, the exact prescribing information may differ between products and countries.
Always verify:
- Manufacturer
- Product name
- Strength
- Dosage form
- Country of authorization
- Official package information